The goal of this study is to see if it is feasible to use electronic questionnaires to measure patient related outcomes before, during, and after radiation for gynecologic cancer in a high-volume radiation oncology clinic.

This is a non-interventional, observational study to collect data on survival, quality of life, and other follow-up information on patients who receive GammaTile therapy.

Patients will undergo a blood draw for a gene classifier test. Some patients will have their physicians informed of the result, and another group of patients will be randomized to be managed by standard of care. Qualifying patients have incidentally identified lung nodules assessed as < 50% risk of cancer.

We have created a workbook about Lynch Syndrome, a genetic condition that means an individual is at high risk of developing certain cancers, and family testing. It is important that patients with Lynch Syndrome tell their family members about their condition so their family members understand their risks and can be tested for Lynch Syndrome too. We are testing our workbook with a small group of patients with Lynch Syndrome to understand if the workbook is helpful in managing their condition and talking to family members.

Screening tool to collect broader demographic and clinical data. Enhance understanding of site specific and trial specific accrual barriers.

The GET SET Study is a research study for women who take medicines to help keep breast cancer from coming back. These medicines are called endocrine therapies and include Tamoxifen and Arimidex. The study will test different kinds of extra support programs, such as daily text message reminders and telephone counseling sessions, for women taking these medicines. We want to learn which support programs help women take their medicine as it is prescribed by their doctor.

This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.

The expected outcome of this proposal is a novel care pathway delivered by pharmacists to improve side effects during oral chemotherapy for patients, a known barrier to adherence, and ultimately to prevent progression and early mortality. Our long-term goal for P3OC is to develop and test new dashboard features to optimize pharmacy care and meet future needs for value-based payment models

The main objective is to glean stakeholders' perspectives about implementing and disseminating an intervention for Black women with breast cancer and their female support people into clinical care.

To collect quantitative data to: -Primarily gain a better understanding of patients' attitudes and preferences regarding end-of-life care management if they were to develop a high-risk skin cancer. To be more specific, we hope to gain a better understanding of how patients weigh their risk of developing skin cancer while taking immunosuppressants versus the risk of transplant rejection should they choose to stop or lower their immunosuppressants. -Determine how far these kidney transplant recipients travel to obtain skin-related care -Determine how frequently kidney transplant recipients obtain skin exams -Determine patients' baseline knowledge regarding risk of skin cancer while taking immunosuppressants, which are medicines that lowers immune systems -Determine the quality of life of individuals with skin cancer who are kidney transplant recipients